# US 2026/0090993 A1 · Pharmaceutical compositions comprising maralixibat and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0090993 A1
- Document ID: US20260090993A1
- Status: Published application
- Kind: A1
- Application number: 19/174,281
- Filed: 2025-04-09
- Published: 2026-04-02
- Earliest claimed: 2023-10-05
- Assignees: Mirum Pharmaceuticals, Inc.
- Applicants: Mirum Pharmaceuticals, Inc.
- Inventors: Parag VED
- Web page: https://patentgrep.com/patent/US20260090993A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2095: {Tabletting processes}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a pharmaceutical composition comprising maralixibat, or a pharmaceutically acceptable salt thereof, as the active ingredient. The invention further relates to the use of the pharmaceutical composition as a solid dosage drug product. The invention also relates to the use of the pharmaceutical composition and the solid dosage drug product described herein for treating cholestatic pruritus and cholestatic liver disease.

## Claims

### Claim at position 1

-170. (canceled)

### Claim 171

A method of treating cholestatic pruritus in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising maralixibat, or a pharmaceutically acceptable salt thereof, and:
(i) a lubricant selected from the group consisting of magnesium stearate, talc, calcium stearate, zinc stearate, sodium stearate, sodium stearyl fumarate, sodium lauryl sulfate, stearic acid, aluminum stearate, leucine, glyceryl behenate, glyceryl dibehenate, glyceryl palmitostearate, hydrogenated vegetable oil, and any combinations thereof, in an amount of about 6% to about 12% (w/w); and
(ii) a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, starch, sodium starch glycolate, and any combinations thereof, in an amount of about 1% to about 10% (w/w).

### Claim 172 (depends on 171)

The method of claim 171, wherein the composition is formulated as a solid dosage form.

### Claim 173 (depends on 171)

The method of claim 171, wherein the composition is formulated as a capsule, a pill, a cachet, a tablet, a granule, a multi-particulate, a mini-tablet, or powder.

### Claim 174 (depends on 171)

The method of claim 171, wherein the composition comprises about 5 mg to about 50 mg maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.

### Claim 175 (depends on 171)

The method of claim 171, wherein the composition comprises about 10% to about 25% (w/w) maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.

### Claim 176 (depends on 171)

The method of claim 171, wherein the composition comprises maralixibat chloride.

### Claim 177 (depends on 171)

The method of claim 171, wherein the maralixibat, or a pharmaceutically acceptable salt thereof is loop milled or pin milled.

### Claim 178 (depends on 171)

The method of claim 171, wherein the particle size distribution of the maralixibat, or a pharmaceutically acceptable salt thereof has a Dv90 of less than about 850 μm.

### Claim 179 (depends on 171)

The method of claim 171, wherein the composition further comprises a glidant selected from the group consisting of silicon dioxide, magnesium stearate, talc, corn starch, and any combinations thereof.

### Claim 180 (depends on 171)

The method of claim 171, wherein the composition further comprises a diluent selected from the group consisting of a sugar, dextrates, dextrin, dextrose, lactose, lactose monohydrate, mannitol, sorbitol, starch, cellulose, and modified celluloses, and any combinations thereof.

### Claim 181 (depends on 171)

The method of claim 171, wherein the subject is a pediatric subject between 2 months and 18 years of age.

### Claim 182 (depends on 171)

The method of claim 171, wherein the subject is an adult who is 18 years of age or older.

### Claim 183 (depends on 171)

The method of claim 171, wherein the cholestatic pruritus is associated with a disease or condition selected from the group consisting of obstructive cholestasis, non-obstructive cholestasis, extrahepatic cholestasis, intrahepatic cholestasis, primary intrahepatic cholestasis, secondary intrahepatic cholestasis, progressive familial intrahepatic cholestasis (PFIC), PFIC type 1, PFIC type 2, PFIC type 3, PFIC type 4, PFIC type 5, PFIC type 6, benign recurrent intrahepatic cholestasis (BRIC), BRIC type 1, BRIC type 2, BRIC type 3, total parenteral nutrition associated cholestasis, paraneoplastic cholestasis, Stauffer syndrome, intrahepatic cholestasis of pregnancy, contraceptive-associated cholestasis, drug-associated cholestasis, infection-associated cholestasis, Dubin-Johnson Syndrome, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), gallstone disease, Alagille syndrome (ALGS), Dubin-Johnson Syndrome, biliary atresia, post-Kasai biliary atresia, post-liver transplantation biliary atresia, post-liver transplantation cholestasis, post-liver transplantation associated liver disease, intestinal failure associated liver disease, bile acid mediated liver injury, MRP2 deficiency syndrome, and neonatal sclerosing cholangitis.

### Claim 184

A method of treating cholestatic pruritus in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical dosage form comprising about 5 mg to about 50 mg maralixibat, or a pharmaceutically acceptable salt thereof, based on the free base weight of maralixibat and:
(iii) a lubricant selected from the group consisting of magnesium stearate, talc, calcium stearate, zinc stearate, sodium stearate, sodium stearyl fumarate, sodium lauryl sulfate, stearic acid, aluminum stearate, leucine, glyceryl behenate, glyceryl dibehenate, glyceryl palmitostearate, hydrogenated vegetable oil, and any combinations thereof, in an amount of about 6% to about 12% (w/w); and
(iv) a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, starch, sodium starch glycolate, and any combinations thereof, in an amount of about 1% to about 10% (w/w).

### Claim 185 (depends on 184)

The method of claim 184, wherein the dosage form is a solid dosage form selected from a capsule, a pill, a cachet, a tablet, a granule, a multi-particulate, a mini-tablet, or powder.

### Claim 186 (depends on 184)

The method of claim 184, wherein the dosage form comprises maralixibat chloride.

### Claim 187 (depends on 184)

The method of claim 184, wherein the dosage form further comprises a glidant selected from the group consisting of silicon dioxide, magnesium stearate, talc, corn starch, and any combinations thereof.

### Claim 188 (depends on 184)

The method of claim 184, wherein the dosage form further comprises a diluent selected from the group consisting of a sugar, dextrates, dextrin, dextrose, lactose, lactose monohydrate, mannitol, sorbitol, starch, cellulose, and modified celluloses, and any combinations thereof.

### Claim 189 (depends on 184)

The method of claim 184, wherein the subject is a pediatric subject between 2 months and 18 years of age.

### Claim 190 (depends on 184)

The method of claim 184, wherein the subject is an adult who is 18 years of age or older.

### Claim 191 (depends on 184)

The method of claim 184, wherein the cholestatic pruritus is associated with a disease or condition selected from the group consisting of obstructive cholestasis, non-obstructive cholestasis, extrahepatic cholestasis, intrahepatic cholestasis, primary intrahepatic cholestasis, secondary intrahepatic cholestasis, progressive familial intrahepatic cholestasis (PFIC), PFIC type 1, PFIC type 2, PFIC type 3, PFIC type 4, PFIC type 5, PFIC type 6, benign recurrent intrahepatic cholestasis (BRIC), BRIC type 1, BRIC type 2, BRIC type 3, total parenteral nutrition associated cholestasis, paraneoplastic cholestasis, Stauffer syndrome, intrahepatic cholestasis of pregnancy, contraceptive-associated cholestasis, drug-associated cholestasis, infection-associated cholestasis, Dubin-Johnson Syndrome, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), gallstone disease, Alagille syndrome (ALGS), Dubin-Johnson Syndrome, biliary atresia, post-Kasai biliary atresia, post-liver transplantation biliary atresia, post-liver transplantation cholestasis, post-liver transplantation associated liver disease, intestinal failure associated liver disease, bile acid mediated liver injury, MRP2 deficiency syndrome, and neonatal sclerosing cholangitis.
